Lupin launches new antibiotic tablet
The drug is used for the treatment of infections caused by various microorganisms and as an adjunctive therapy in severe acne
Pharma Major Lupin today announced the launch of Doxycycline Hyclate Tablet USP, 100 mg. The drug is used for the treatment of infections caused by various microorganisms and as an adjunctive therapy in severe acne.
The company had earlier received approval from the United States Food and Drug Administration (FDA) for the drug.
"Doxycycline Hyclate Tablet USP, 100 mg is an AB rated generic equivalent of Pfizer Inc’s Vibra-Tabs®, 100 mg," the company said in a statement.
According to market research firm IMS MAT , Doxycycline Hyclate Tablet USP, 100 mg has annual sales prospect of approximately $144 million in the US.
Lupin, a manufacturer of branded plus generic formulations, biotechnology products and APIs, earns 47% from its US business.
For the financial year ended March 31, 2017, Lupin’s Consolidated sales and Net profit stood at Rs 171,19.8 crore ($2.55 billion) and Rs 25,57.5 crore ($381 million), respectively.
At 2.40 pm, the company's stock was trading at 923, up 0.50% over the previous day's close on the BSE.
Get Latest Business News, Stock Market Updates and Videos; Check your tax outgo through Income Tax Calculator and save money through our Personal Finance coverage. Check Business Breaking News Live on Zee Business Twitter and Facebook. Subscribe on YouTube.
RECOMMENDED STORIES
Power of Compounding: How many years will it take to reach Rs 3 crore corpus if your monthly SIP is Rs 4,000, Rs 5,000, or Rs 6,000
Power of Compounding: Salary Rs 25,000 per month; is it possible to create over Rs 2.60 crore corpus; understand it through calculations
Reduce Home Loan EMI vs Reduce Tenure: Rs 75 lakh, 25-year loan; which option can save Rs 25 lakh and 64 months and how? Know here
Top 7 Large and Mid Cap Mutual Funds with Best SIP Returns in 5 Years: No. 1 fund has turned Rs 15,000 monthly SIP investment into Rs 20,54,384; know about others
New Year Pick by Anil Singhvi: This smallcap stock can offer up to 75% return in long term - Check targets
02:50 PM IST